Japan· JP-1319752Q1083
オロパタジン塩酸塩
A olopatadine product containing オロパタジン塩酸塩, registered in Japan by 千寿製薬, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Olopatadine is registered in 2 of 19 countries.
Countries holding a registration under ATC R01AC08 (olopatadine), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Olopatadine · ATC R01AC08
2 / 19 countries
- Japan
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- オロパタジン塩酸塩
- Manufacturer
- 千寿製薬
- Country
- Japan (JP)
- ATC code
- R01AC08
- ATC class
- Olopatadine
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
454 interactions on record for olopatadine.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Olopatadine · interactions on record
454 records
- 2 severe
- 310 moderate
- 142 info
Most severe, free to view
- Sodium oxybateN01AX11severe
- DicycloverineA03AA07moderate
- AtropineA03BA01moderate
- HyoscyamineA03BA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R01AC08
Olopatadine, as other registers publish it.
- United Statesolopatadine hydrochlorideBryant Ranch Prepack
- United Statesolopatadine hydrochlorideBryant Ranch Prepack
- United Statesolopatadine hydrochloridePadagis Israel Pharmaceuticals Ltd
- United StatesOlopatadine HydrochlorideApotex Corp.
- United StatesOlopatadine HydrochlorideApotex Corp.
- United StatesOlopatadine HydrochlorideAmneal Pharmaceuticals LLC
- United StatesOLOPATADINE HYDROCHLORIDESomerset Therapeutics, LLC
- Japanオロパタジン塩酸塩
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd945788-fbc9-493d-8d74-5f1bd803f2eb GET /v1/drugs/bd945788-fbc9-493d-8d74-5f1bd803f2eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．１％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1319752Q1083",
"category": "外用薬",
"price_yen": 31.4,
"generic_name": "オロパタジン塩酸塩",
"product_name_jp": null,
"therapeutic_class": "1319",
"transitional_expiry": null
}See everything about olopatadine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.